STOCK TITAN
  1. Home
  2. News
  3. RAMMF

RAMM PHARMA CORP - RAMMF STOCK NEWS

Welcome to our dedicated page for RAMM PHARMA news (Ticker: RAMMF), a resource for investors and traders seeking the latest updates and insights on RAMM PHARMA stock.

RAMM PHARMA CORP (RAMMF) is a pharmaceutical company dedicated to developing innovative cannabinoid-based medications to address a wide range of medical conditions. With a focus on research, development, and commercialization, RAMM PHARMA is at the forefront of the emerging market for cannabinoid therapeutics. The company's proprietary technology and strategic partnerships enable them to create high-quality, effective treatments that improve patient outcomes. RAMM PHARMA's commitment to scientific rigor and patient care sets them apart in the pharmaceutical industry.

News

RAMM Pharma Corp. Provides Update on Litigation

Rhea-AI Summary

RAMM Pharma Corp. has updated its shareholders on ongoing litigation involving Sergio Martines and Naturale Science Inc. The trial occurred between April 29, 2024, and May 16, 2024, with the judge reserving the decision. Martines and Naturale Science Inc. are demanding approximately C$3 million from RAMM for breach of contract, specific performance, and out-of-pocket expenses. In response, RAMM has filed a counterclaim seeking C$14 million in damages for alleged fraudulent misrepresentation related to its acquisition of Canapar in June 2021. RAMM has accrued C$300,000 in its financial statements for possible liabilities, which may be adjusted in future reports.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

RAMM Pharma Corp. Announces Corporate Update

Rhea-AI Summary
RAMM Pharma Corp. diversifies its product portfolio by launching botanical-derived food supplements under the Marishanti brand through its subsidiary Hempoland. The company aims to reduce exposure to cannabis-based products and tap into the growing global plant-extract market. The initial product line includes well-researched botanical ingredients with proven health benefits, with additional SKUs in development. The market for plant extracts is expanding rapidly, driven by increasing consumer demand for natural and healthy products, presenting a significant growth opportunity for RAMM.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

RAMM Pharma Corp. Announces Corporate Update

Rhea-AI Summary
RAMM Pharma Corp. announced a non-brokered private placement of up to 20,000,000 units at $0.05 per unit, aiming to raise $1,000,000 for working capital and corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News

RAMM Pharma Corp. Announces Corporate Update

Rhea-AI Summary
RAMM Pharma Corp. (CSE: RAMM) announced a non-brokered private placement of up to 20,000,000 units at a price of $0.05 per unit, aiming to raise $1,000,000 for working capital and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

RAMM Pharma Corp. Announces Corporate Update

Rhea-AI Summary
RAMM Pharma Corp. (CSE: RAMM) has rescinded a grant of 2,000,000 stock options made to the chief operating officer of Canapar Corp., a subsidiary of the Company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

RAMM Pharma Corp. Announces Corporate Update.

Rhea-AI Summary
RAMM Pharma Corp (CSE: RAMM) Announces Non-Brokered Private Placement Offering
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News

RAMM Pharma Corp. Announces Corporate Update

Rhea-AI Summary
RAMM Pharma Corp. announces non-brokered private placement and normal course issuer bid
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

RAMM Pharma Corp. Announces Clarification of its Corporate Update of September 12th

Rhea-AI Summary
RAMM Pharma Corp. announced a non-brokered private placement of up to 20,000,000 units at a price of $0.05 per unit for total gross proceeds of up to $1,000,000. The proceeds will be used for working capital and general corporate purposes. The offering was expected to close on September 26, 2023. Additionally, the company announced a normal course issuer bid to purchase up to 5% of the current number of issued and outstanding common shares. The company intends to proceed with the private placement, but it may require shareholder approval due to CSE's policy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

RAMM Pharma Corp. Announces Corporate Update

Rhea-AI Summary
RAMM Pharma Corp. cancels non-brokered private placement due to CSE's assessment of sufficient cash reserves
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News

RAMM Pharma Corp. Announces Non-Brokered Private Placement and Intention to Commence Normal Course Issuer Bid

Rhea-AI Summary
RAMM Pharma Corp. plans to complete a non-brokered private placement of up to 20,000,000 units at $0.05 per unit for gross proceeds of up to $1,000,000. The proceeds will be used for working capital and general corporate purposes. The company also intends to start a normal course issuer bid to purchase up to 5% of the current number of issued and outstanding Common Shares. Insiders plan to acquire 10,000,000 units in the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none

FAQ

What is the market cap of RAMM PHARMA (RAMMF)?

The market cap of RAMM PHARMA (RAMMF) is approximately 15.2M.

What is RAMM PHARMA CORP (RAMMF) focused on?

RAMM PHARMA is dedicated to developing innovative cannabinoid-based medications.

What sets RAMM PHARMA apart in the pharmaceutical industry?

RAMM PHARMA's commitment to scientific rigor and patient care distinguishes them from competitors.

What are some key aspects of RAMM PHARMA's operations?

RAMM PHARMA focuses on research, development, and commercialization of cannabinoid therapeutics.

How does RAMM PHARMA collaborate with partners?

RAMM PHARMA strategically partners with other organizations to enhance their product development and market reach.

What is RAMM PHARMA's approach to creating medications?

RAMM PHARMA leverages proprietary technology to create high-quality, effective treatments.

What is the significance of RAMM PHARMA's research?

RAMM PHARMA's research aims to address a wide range of medical conditions and improve patient outcomes.

How can I contact RAMM PHARMA for more information?

For further information, please contact José Roldan, Interim CFO, at +598 2513 99 58 or info@rammpharma.com.

Are RAMM PHARMA's products backed by scientific evidence?

The beneficial properties of RAMM PHARMA's products have been extensively tested and documented in academic reviews and research papers.

Where can I find a photo related to RAMM PHARMA?

A photo accompanying the latest announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/fab821be-3712-40a7-a7d8-da7ecb69b28b

What is the focus of RAMM PHARMA's innovative treatments?

RAMM PHARMA's treatments focus on utilizing cannabinoids to address a wide range of medical conditions.
Stock RAMMF logo
RAMM PHARMA CORP

OTC:RAMMF

RAMMF Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

RAMMF Stock Data

15.16M
90.71M
25.53%
1.84%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
Canada
Toronto